tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

VTGN Stock Latest News

VistaGen Completes Patient Phase in Key Clinical Trial
Company AnnouncementsVistaGen Completes Patient Phase in Key Clinical Trial
3d ago
8K
VTGN
VistaGen Therapeutics: Promising Prospects for Fasedienol in Social Anxiety Disorder
PremiumRatings
VistaGen Therapeutics: Promising Prospects for Fasedienol in Social Anxiety Disorder
3d ago
VTGN
Vistagen completes portion of PALISADE-3 trial
PremiumThe Fly
Vistagen completes portion of PALISADE-3 trial
5d ago
VTGN
Analysts Predict Up to 550% Rally for These 2 ‘Strong Buy’ Penny Stocks
PremiumMarket News
Analysts Predict Up to 550% Rally for These 2 ‘Strong Buy’ Penny Stocks
7d ago
ACRV
VTGN
VistaGen Therapeutics Appoints Paul R. Edick to Board
PremiumCompany Announcements
VistaGen Therapeutics Appoints Paul R. Edick to Board
9d ago
8K
VTGN
Vistagen’s Phase 3 Trial: A Potential Game-Changer for Anxiety Treatment?
PremiumCompany AnnouncementsVistagen’s Phase 3 Trial: A Potential Game-Changer for Anxiety Treatment?
11d ago
VTGN
Vistagen’s Phase 3 Trial of Fasedienol Nasal Spray: A Potential Game-Changer for Anxiety Treatment
Premium
Company Announcements
Vistagen’s Phase 3 Trial of Fasedienol Nasal Spray: A Potential Game-Changer for Anxiety Treatment
11d ago
VTGN
Vistagen’s Promising Phase 2 Trial for Anxiety Treatment: A Market Game Changer?
Premium
Company Announcements
Vistagen’s Promising Phase 2 Trial for Anxiety Treatment: A Market Game Changer?
11d ago
VTGN
VistaGen Therapeutics CFO Resignation Announced
PremiumCompany Announcements
VistaGen Therapeutics CFO Resignation Announced
2M ago
8K
VTGN
Vistagen initiated with a Buy at Lucid Capital
PremiumThe Fly
Vistagen initiated with a Buy at Lucid Capital
2M ago
VTGN
Vistagen Therapeutics’ Earnings Call: Progress Amid Challenges
PremiumCompany Announcements
Vistagen Therapeutics’ Earnings Call: Progress Amid Challenges
3M ago
VTGN
VistaGen Therapeutics: Strong Cash Position and Promising Drug Pipeline Drive Buy Rating
PremiumRatings
VistaGen Therapeutics: Strong Cash Position and Promising Drug Pipeline Drive Buy Rating
3M ago
VTGN
Vistagen Therapeutics Reports Progress in Clinical Trials
PremiumCompany AnnouncementsVistagen Therapeutics Reports Progress in Clinical Trials
3M ago
VTGN
VistaGen Reports Q1 2026 Financial Results and Update
Premium
Company Announcements
VistaGen Reports Q1 2026 Financial Results and Update
3M ago
8K
VTGN
Vistagen reports Q1 EPS (47c), consensus (44c)
Premium
The Fly
Vistagen reports Q1 EPS (47c), consensus (44c)
3M ago
VTGN
Vistagen Appoints Elissa Cote as Chief Development Officer
PremiumCompany Announcements
Vistagen Appoints Elissa Cote as Chief Development Officer
5M ago
8K
VTGN
Vistagen appoints Elissa Cote as Chief Corporate Development Officer
PremiumThe Fly
Vistagen appoints Elissa Cote as Chief Corporate Development Officer
5M ago
VTGN
Vistagen Therapeutics’ Earnings Call Highlights Progress and Challenges
PremiumCompany Announcements
Vistagen Therapeutics’ Earnings Call Highlights Progress and Challenges
5M ago
VTGN
Vistagen Therapeutics Reports Progress in Clinical Trials
PremiumCompany Announcements
Vistagen Therapeutics Reports Progress in Clinical Trials
5M ago
VTGN
Closing Bell Movers: Futures extend decline amid Middle East tension
PremiumThe FlyClosing Bell Movers: Futures extend decline amid Middle East tension
5M ago
LZB
ZTS
VistaGen Files Prospectus to Raise $175 Million
Premium
Company Announcements
VistaGen Files Prospectus to Raise $175 Million
5M ago
8K
VTGN
Vistagen reports FY25 EPS ($1.67), two estimates ($1.74)
Premium
The Fly
Vistagen reports FY25 EPS ($1.67), two estimates ($1.74)
5M ago
VTGN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >